A Personalized Mobile Application Providing Temperature-Related Health Risk Warnings and Protective Recommendations for Patients With Chronic Obstructive Pulmonary Disease
2026年6月14日 更新者：Tiantian Li
Effectiveness of A Personalized Mobile Application Providing Temperature-Related Health Risk Warnings and Protective Recommendations for Patients With Chronic Obstructive Pulmonary Disease
This study will test whether a personalized mobile application that provides temperature-related health risk warnings and protective recommendations can reduce acute exacerbations in people with chronic obstructive pulmonary disease (COPD).
Researchers will compare participants who receive the mobile application in addition to usual care with those who receive usual care alone.
The main question is whether the mobile application reduces the number of COPD acute exacerbation events over 12 months.
The study will also evaluate secondary outcomes including quality of life, functional capacity, symptoms, psychological status, physiological and biochemical indicators, environmental temperature risk perception, and participants' use of the mobile application.
調査の概要
状態
まだ募集していません
条件
詳細な説明
This study is a proof-of-concept study using a cluster randomized controlled design, with hospitals serving as the unit of randomization.
Four eligible hospitals in Beijing will be selected as study sites, and each hospital together with all eligible participants enrolled at that site will be treated as one cluster.
Clusters will be randomly assigned in a 1:1 ratio to the intervention group or the control group.
In addition to usual COPD care, participants in the intervention group will receive temperature-related health risk warning messages and corresponding protective recommendations generated from real-time meteorological data and individual characteristics through the personalized mobile application.
Participants in the control group will receive usual COPD care only without access to the mobile application.
The study includes a baseline assessment and a 12-month follow-up period.
Study visits will occur at baseline and at 3, 6, 9, and 12 months after enrollment.
Baseline assessments will include demographic information, air-conditioner use, smoking and alcohol consumption, health status, acute exacerbation events, quality of life, functional capacity, symptoms, psychological status, environmental temperature perception, and physiological and biochemical indicators.
Follow-up assessments will collect acute exacerbation events, quality of life, functional capacity, symptoms, psychological status, physiological and biochemical indicators, environmental temperature perception and participants' use of the mobile application.
Due to the cluster design and the nature of the mobile application intervention, study participants and research staff who collect visit data will be unmasked.
However, data analysts and members of the endpoint adjudication committee will remain masked to the randomization assignments.
研究の種類
介入
入学 (推定)
240
段階
- 適用できない
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
- 名前：Can Zhang, Ph.D.
- 電話番号：+8613655181384
- メール：zhangcan@nieh.chinacdc.cn
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
いいえ
説明
Hospital inclusion criteria:
- Tertiary hospitals;
- Hospitals with respiratory wards that admit patients with COPD;
- Hospitals with a well-established electronic health record system and follow-up capability;
- Hospitals able to assign a study coordinator.
Patient inclusion criteria:
- Age >=40 years and <=80 years, with no restriction on sex;
- Patients with stable chronic obstructive pulmonary disease;
- At least 1 severe acute exacerbation requiring hospitalization, or at least 2 moderate acute exacerbations requiring outpatient or emergency care, within the previous year;
- Local permanent residents with a duration of residence >=6 months;
- Patients who voluntarily agree to participate, are expected to have good adherence, are able to sign informed consent;
- Patients who own a smartphone or other smart device.
Hospital exclusion criteria:
- Primary hospitals or private hospitals;
- Hospitals unable to cooperate with the study protocol.
Patient exclusion criteria:
- Patients with asthma;
- Women who are known to be pregnant or breastfeeding, or who have a positive pregnancy test before cluster randomization;
- Patients with other diseases that may affect participation in the trial, such as refractory hypertension or severe aphasia;
- Patients currently receiving psychiatric or psychological treatment that may contaminate study results;
- Expected survival time <1 year, such as in those with malignant tumors or severe cardiopulmonary disease;
- Participation in other interventional clinical studies that may affect outcome assessment;
- Any other circumstances in which the investigator considers the patient unsuitable for participation in this study or at significant risk, such as cognitive impairment preventing understanding of and/or compliance with study procedures and/or follow-up.
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：防止
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Personalized Temperature Risk Intervention + Usual COPD Care
|
This study implements a digital early warning intervention targeting personalized temperature-related health risks.
The mobile application integrates real-time meteorological data and individual characteristics to generate risk levels and deliver tailored health alerts and guidance aimed at supporting risk management and reducing exposure-related health risks.
|
|
介入なし：Usual COPD Care
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of COPD Acute Exacerbations
時間枠：12 months after baseline
|
Total number of acute exacerbations of COPD managed at home, via outpatient visits, emergency department visits, or hospitalizations.
|
12 months after baseline
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Home-managed COPD Acute Exacerbations
時間枠：6 and 12 months after baseline
|
Number of home-managed COPD acute exacerbations
|
6 and 12 months after baseline
|
|
Number of Outpatient-managed COPD Acute Exacerbations
時間枠：6 and 12 months after baseline
|
Number of outpatient-managed COPD acute exacerbations
|
6 and 12 months after baseline
|
|
Number of Emergency Department-managed COPD Acute Exacerbations
時間枠：6 and 12 months after baseline
|
Number of emergency department-managed COPD acute exacerbations
|
6 and 12 months after baseline
|
|
Number of Hospitalized COPD Acute Exacerbations
時間枠：6 and 12 months after baseline
|
Number of hospitalized COPD acute exacerbations
|
6 and 12 months after baseline
|
|
Changes in St. George's Respiratory Questionnaire for COPD Patients Score
時間枠：3, 6, 9, and 12 months after baseline
|
The St. George's Respiratory Questionnaire for COPD patients (SGRQ-C) score ranges from 0 to 100.
Higher scores indicate a worse outcome (poorer health-related quality of life).
|
3, 6, 9, and 12 months after baseline
|
|
Changes in EuroQol 5-Dimension 5-Level Score
時間枠：3, 6, 9, and 12 months after baseline
|
The EuroQol 5-Dimension 5-Level (EQ-5D-5L) score consists of two parts: a questionnaire and a visual analogue scale (VAS).
The questionnaire includes five dimensions, where higher scores indicate worse health status.
The VAS asks respondents to rate their overall health status on a 0-100 scale.
Higher scores on the VAS mean a better outcome (better self-rated health status).
|
3, 6, 9, and 12 months after baseline
|
|
Change from Baseline in Forced Expiratory Volume in 1 Second
時間枠：6 and 12 months after baseline
|
Forced Expiratory Volume in 1 Second (FEV1) will be measured in liters using spirometry.
|
6 and 12 months after baseline
|
|
Change from Baseline in Forced Vital Capacity
時間枠：6 and 12 months after baseline
|
Forced Vital Capacity (FVC) will be measured in liters using spirometry.
|
6 and 12 months after baseline
|
|
Change from Baseline in Percent Predicted FEV1
時間枠：6 and 12 months after baseline
|
Percent Predicted Forced Expiratory Volume in 1 Second (FEV1%pred) will be calculated from spirometry and expressed as a percentage of the predicted value.
|
6 and 12 months after baseline
|
|
Changes in Blood Pressure
時間枠：3, 6, 9, and 12 months after baseline
|
Measured using a sphygmomanometer.
|
3, 6, 9, and 12 months after baseline
|
|
Number of Participants With Abnormal Electrocardiogram Readings
時間枠：3, 6, 9, and 12 months after baseline
|
Abnormal electrocardiogram (ECG) readings will be identified from standard clinical ECG reports by qualified physicians.
The total number of participants with these abnormal readings will be counted.
A lower number of participants with abnormal ECG readings means a better outcome (better cardiac safety profile).
|
3, 6, 9, and 12 months after baseline
|
|
Changes in Blood Oxygen Saturation
時間枠：3, 6, 9, and 12 months after baseline
|
Measured using a pulse oximeter.
|
3, 6, 9, and 12 months after baseline
|
|
Changes in Modified Medical Research Council Score
時間枠：3, 6, 9, and 12 months after baseline
|
The modified Medical Research Council (mMRC) score ranges from 0 to 4. Higher scores mean a worse outcome (more severe dyspnea).
|
3, 6, 9, and 12 months after baseline
|
|
Changes in the COPD Assessment Test Questionnaire Score
時間枠：3, 6, 9, and 12 months after baseline
|
The COPD Assessment Test (CAT) total score ranges from 0 to 40.
Higher scores mean a worse outcome (a greater impact of COPD on patient's health status).
|
3, 6, 9, and 12 months after baseline
|
|
Changes in 7-item Generalized Anxiety Disorder Questionnaire Score
時間枠：3, 6, 9, and 12 months after baseline
|
The 7-item Generalized Anxiety Disorder (GAD-7) questionnaire score ranges from 0 to 21.
Higher scores mean a worse outcome (more severe anxiety symptoms).
|
3, 6, 9, and 12 months after baseline
|
|
Changes in 9-item Patient Health Questionnaire Score
時間枠：3, 6, 9, and 12 months after baseline
|
The 9-item Patient Health Questionnaire (PHQ-9) score ranges from 0 to 27.
Higher scores mean a worse outcome (more severe depressive symptoms).
|
3, 6, 9, and 12 months after baseline
|
|
Changes in Environmental Temperature Risk Perception Score
時間枠：3, 6, 9, and 12 months after baseline
|
Used to assess the participant's awareness and perception of health risks related to environmental temperature on the basis of the Temperature Risk Perception Questionnaire.
|
3, 6, 9, and 12 months after baseline
|
|
Number of Participants With Abnormal Complete Blood Count Results
時間枠：12 months after baseline
|
Abnormal complete blood count (CBC) readings will be identified from standard clinical CBC reports by qualified physicians.
The total number of participants with these abnormal readings will be counted.
A lower number of participants with abnormal CBC readings means a better outcome (better clinical safety profile).
|
12 months after baseline
|
|
Frequency of Personalized Mobile Application Use
時間枠：3, 6, 9, and 12 months after baseline
|
Assessed using backend data statistics from the personalized Mobile Application.
|
3, 6, 9, and 12 months after baseline
|
|
Satisfaction with Personalized Mobile Application
時間枠：3, 6, 9, and 12 months after baseline
|
Participant satisfaction with the personalized mobile application will be evaluated using the 10-item System Usability Scale (SUS).
The SUS total score ranges from 0 to 100.
Higher scores mean a better outcome (greater perceived usability and higher patient satisfaction with the mobile application).
|
3, 6, 9, and 12 months after baseline
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
スポンサー
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (推定)
2026年6月1日
一次修了 (推定)
2027年8月1日
研究の完了 (推定)
2027年8月1日
試験登録日
最初に提出
2026年6月9日
QC基準を満たした最初の提出物
2026年6月14日
最初の投稿 (実際)
2026年6月18日
学習記録の更新
投稿された最後の更新 (実際)
2026年6月18日
QC基準を満たした最後の更新が送信されました
2026年6月14日
最終確認日
2026年6月1日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- COPD-202606
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
いいえ
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。